JP2017536414A - 血管性眼疾患を処置するための方法および製剤 - Google Patents

血管性眼疾患を処置するための方法および製剤 Download PDF

Info

Publication number
JP2017536414A
JP2017536414A JP2017545861A JP2017545861A JP2017536414A JP 2017536414 A JP2017536414 A JP 2017536414A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A JP2017536414 A JP 2017536414A
Authority
JP
Japan
Prior art keywords
ang
administered
inhibitor
vegf antagonist
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017545861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017536414A5 (cg-RX-API-DMAC7.html
Inventor
ロバート・エル・ヴィッティ
クリスティン・エー・エリクソン
カレン・ダブリュ・チュー
スタンレー・ジェイ・ウィーガンド
ケイタイ・カオ
アイヴァン・ビー・ロボフ
ソーラブ・ワドワ
ケネス・エス・グレアム
ダニエル・ディックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2017536414A publication Critical patent/JP2017536414A/ja
Publication of JP2017536414A5 publication Critical patent/JP2017536414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
JP2017545861A 2014-11-25 2015-11-19 血管性眼疾患を処置するための方法および製剤 Pending JP2017536414A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462084003P 2014-11-25 2014-11-25
US62/084,003 2014-11-25
US201562147232P 2015-04-14 2015-04-14
US62/147,232 2015-04-14
US14/943,490 2015-11-17
US14/943,490 US20160144025A1 (en) 2014-11-25 2015-11-17 Methods and formulations for treating vascular eye diseases
PCT/US2015/061543 WO2016085750A1 (en) 2014-11-25 2015-11-19 Methods and formulations for treating vascular eye diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020201473A Division JP2021046431A (ja) 2014-11-25 2020-12-04 血管性眼疾患を処置するための方法および製剤

Publications (2)

Publication Number Publication Date
JP2017536414A true JP2017536414A (ja) 2017-12-07
JP2017536414A5 JP2017536414A5 (cg-RX-API-DMAC7.html) 2018-12-27

Family

ID=56009149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017545861A Pending JP2017536414A (ja) 2014-11-25 2015-11-19 血管性眼疾患を処置するための方法および製剤
JP2020201473A Pending JP2021046431A (ja) 2014-11-25 2020-12-04 血管性眼疾患を処置するための方法および製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020201473A Pending JP2021046431A (ja) 2014-11-25 2020-12-04 血管性眼疾患を処置するための方法および製剤

Country Status (18)

Country Link
US (3) US20160144025A1 (cg-RX-API-DMAC7.html)
EP (1) EP3224278A4 (cg-RX-API-DMAC7.html)
JP (2) JP2017536414A (cg-RX-API-DMAC7.html)
KR (1) KR20170087950A (cg-RX-API-DMAC7.html)
CN (1) CN107001457A (cg-RX-API-DMAC7.html)
AU (1) AU2015353838A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017009807A2 (cg-RX-API-DMAC7.html)
CA (1) CA2968522A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001188A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017004715A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791168A1 (cg-RX-API-DMAC7.html)
IL (1) IL252159B (cg-RX-API-DMAC7.html)
MA (2) MA41028A (cg-RX-API-DMAC7.html)
MX (1) MX2017006129A (cg-RX-API-DMAC7.html)
PE (1) PE20170900A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017500834A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703609UA (cg-RX-API-DMAC7.html)
WO (1) WO2016085750A1 (cg-RX-API-DMAC7.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2586459T3 (en) 2005-03-25 2017-09-11 Regeneron Pharma VEGF antagonist formulations
ES2828739T3 (es) 2006-04-07 2021-05-27 Aerpio Pharmaceuticals Inc Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8569348B2 (en) 2009-07-06 2013-10-29 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
HK1218071A1 (zh) 2013-02-21 2017-02-03 Rsem, Limited Partnership Sema3a在预防和治疗眼渗透性过高症中的抑制
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
WO2016153877A1 (en) * 2015-03-26 2016-09-29 Eyekor, Llc Image analysis
EP3977994B1 (en) 2015-09-23 2024-04-24 EyePoint Pharmaceuticals, Inc. Activators of tie-2 for use in treating intraocular pressure
JP7088454B2 (ja) 2015-12-30 2022-06-21 コディアック サイエンシーズ インコーポレイテッド 抗体および抗体複合体
SG11201900464TA (en) 2016-07-20 2019-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
US20200056186A1 (en) 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
JPWO2018070390A1 (ja) * 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN110709104A (zh) * 2017-05-06 2020-01-17 瑞泽恩制药公司 用aplnr拮抗剂和vegf抑制剂治疗眼部病症的方法
US20190056350A1 (en) * 2017-08-18 2019-02-21 Regeneron Pharmaceuticals, Inc. Image capillary isoelectric focusing to analyze protein variants in a sample matrix
CN111465407A (zh) * 2017-11-30 2020-07-28 瑞泽恩制药公司 使用vegf拮抗剂治疗生血管性眼病
KR102494021B1 (ko) * 2017-12-22 2023-02-06 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
ES3009668T3 (en) 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
CN111699004A (zh) * 2018-02-06 2020-09-22 豪夫迈·罗氏有限公司 眼科疾病的治疗
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
CN112912104A (zh) * 2018-08-17 2021-06-04 三钰生物科技股份有限公司 抗血管新生融合蛋白及其用途
CN109598628B (zh) * 2018-11-30 2022-09-20 平安医疗健康管理股份有限公司 医保欺诈行为的识别方法、装置、设备及可读存储介质
US11945859B2 (en) 2018-12-18 2024-04-02 Novartis Ag Protein solution formulation containing high concentration of an anti-VEGF antibody
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
EP3962482A4 (en) 2019-04-29 2023-01-11 EyePoint Pharmaceuticals, Inc. TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL
CN110423281B (zh) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021220138A1 (en) * 2020-04-29 2021-11-04 Novartis Ag A computer-implemented system and method for assessing a level of activity of a disease or condition in a patient's eye
CA3182893A1 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
JP2023530187A (ja) * 2020-06-22 2023-07-13 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド 抗ａｎｇ－２抗体とその用途
EP4186492A4 (en) * 2020-07-24 2024-08-14 Pangen Biotech Inc. Ophthalmic liquid composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528708A (ja) * 2003-06-30 2007-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびその治療的使用
JP2013500970A (ja) * 2009-07-29 2013-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトアンジオポイエチン−２に対する高親和性ヒト抗体

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
RU2432155C3 (ru) * 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
CN102458471A (zh) * 2009-05-28 2012-05-16 葛兰素集团有限公司 用于治疗或预防眼病的TNFα拮抗剂和VEGF拮抗剂的组合
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) * 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
EP3222285A1 (en) * 2011-01-13 2017-09-27 Regeneron Pharmaceuticals, Inc. Use of a vegf antagonist to treat angiogenic eye disorders
CA2861062A1 (en) * 2012-01-23 2013-08-01 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ang2 antibodies
US9695233B2 (en) * 2012-07-13 2017-07-04 Roche Glycart Ag Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases
CN104968678B (zh) * 2012-12-05 2018-12-11 诺华股份有限公司 靶向epo的抗体的组合物和方法
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
RU2676303C2 (ru) * 2013-07-11 2018-12-27 Новартис Аг Использование антагониста vegf для лечения ретролентальной фиброплазии
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528708A (ja) * 2003-06-30 2007-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびその治療的使用
JP2013500970A (ja) * 2009-07-29 2013-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトアンジオポイエチン−２に対する高親和性ヒト抗体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRITISH JOURNAL OF OPHTHALMOLOGY, vol. 98, no. 12, JPN6019032462, July 2014 (2014-07-01), pages 1636 - 1641, ISSN: 0004318719 *
CLINICALTRIALS.GOV ARCHIVE, vol. NCT01997164, JPN6020000979, 22 November 2013 (2013-11-22), ISSN: 0004318723 *
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 55, JPN6020000977, April 2014 (2014-04-01), pages 2356, ISSN: 0004318721 *
NATURE BIOTECHNOLOGY, vol. 32, no. 8, JPN6020000978, August 2014 (2014-08-01), pages 701 - 702, ISSN: 0004318722 *
OPHTHALMOLOGY, vol. 121, no. 11, JPN6019032464, July 2014 (2014-07-01), pages 2247 - 2254, ISSN: 0004318720 *

Also Published As

Publication number Publication date
EA201791168A1 (ru) 2017-09-29
PH12017500834A1 (en) 2017-10-30
CO2017004715A2 (es) 2017-09-20
IL252159A0 (en) 2017-07-31
KR20170087950A (ko) 2017-07-31
US20170080086A1 (en) 2017-03-23
US20160144025A1 (en) 2016-05-26
SG11201703609UA (en) 2017-06-29
JP2021046431A (ja) 2021-03-25
MA40306A1 (fr) 2019-03-29
CL2017001188A1 (es) 2017-11-24
EP3224278A4 (en) 2018-07-11
MX2017006129A (es) 2018-04-10
WO2016085750A1 (en) 2016-06-02
US20190117767A1 (en) 2019-04-25
CN107001457A (zh) 2017-08-01
IL252159B (en) 2021-03-25
BR112017009807A2 (pt) 2018-02-27
AU2015353838A1 (en) 2017-06-08
MA41028A (fr) 2017-10-03
US11071780B2 (en) 2021-07-27
CA2968522A1 (en) 2016-06-02
PE20170900A1 (es) 2017-07-12
EP3224278A1 (en) 2017-10-04

Similar Documents

Publication Publication Date Title
US11071780B2 (en) Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab
JP7273204B2 (ja) 眼科疾患の処置
US20100111963A1 (en) Method for treating age-related macular degeneration
AU2022275786B2 (en) Extended, high dose VEGF antagonist regimens for treatment of angiogenic eye disorders
TW202400215A (zh) 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
US11104730B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
TW202400214A (zh) 用於血管新生眼睛病症之治療之延長高劑量ｖｅｇｆ拮抗劑方案
AU2018266324B2 (en) Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
JP2017532342A (ja) 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体
KR20220062279A (ko) 안질환의 치료 방법
HK1241908A1 (en) Methods and formulations for treating vascular eye diseases
EA043390B1 (ru) Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804